Therapy for fungal diseases: opportunities and priorities
Open accessAbstract
This article provides a perspective on the current status of drug therapy for invasive fungal diseases, together with priorities for the future development of novel compounds. Key opportunities for new drugs include production of orally bioavailable agents for the treatment of invasive aspergillosis, invasive candidiasis, cryptococcal meningitis and mucosal and urinary Candida infections. Orally bioavailable agents for the treatment of chronic pulmonary and allergic aspergillosis are also required, as well as new potent drugs against a range of medically important moulds. Antifungal resistance is a problem in certain contexts, but is generally less of a problem than bacterial infections. Earlier and more complete mycological diagnosis and improvements in underlying risk estimation will improve outcomes. The limitations of the current antifungal agents and opportunities for new developments are discussed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pharmacokinetic parameters of the main antifungal agents are not always directly comparable because data derive from multiple sources and trials.
“Pharmacokinetic parameters are not always directly comparable because data derive from multiple sources and trials [20].”
From <i>Candida</i>Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [20]
Only few classes of antifungal agents are currently available to treat mucosal or systemic infections with Candida spp.
“Although the antifungal drugs used in clinical treatments appear to be diverse and numerous, only few classes of antifungal agents are currently available to treat mucosal or systemic infections with Candida spp. (Figure 1) [18–20].”
From <i>Candida</i>Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 102 · Cited by 314
- Authors
- Denning, D. W., & Hope, W. W.
- Affiliations
- Manchester Academic Health Science Centre (GB)
- Corresponding author
- Denning, David W.
- Venue
- Trends in Microbiology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 18
- Issue
- 5
- Pages
- 195-204
- ISSN
- 0966-842X (ISSN-L)
- OpenAlex
- W1969289841
- Cited by
- 314
- References
- 102
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 15 · 2022: 19 · 2021: 18 · 2020: 23 · 2019: 13 · 2018: 24 · 2017: 23 · 2016: 23 · 2015: 26 · 2014: 24 · 2013: 28 · 2012: 26
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Trends in Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- invasive fungal infections, antifungal drug development, invasive aspergillosis, invasive candidiasis, cryptococcal meningitis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, mold infections, antifungal resistance, oral bioavailability, mycological diagnosis, risk estimation
- MeSH terms
- Antifungal Agents, Mycoses, Drug Resistance, Fungal, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
